checkAd

     164  0 Kommentare First patient dosed in monalizumab Phase 3 clinical trial triggers $50M payment from AstraZeneca - Seite 4

    This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

    For additional information, please contact:

    Investors

     

    Innate Pharma         

    Tel.: +33 (0)4 30 30 30 30

    investors@innate-pharma.com



     

          		Media

     

    Innate Pharma 

    Tracy Rossin (Global/US)

    Tel.: +1 240 801 0076

    Tracy.Rossin@innate-pharma.com

     

    ATCG Press

    Marie Puvieux (France)

    Tel.: +33 (0)9 81 87 46 72

    innate-pharma@atcg-partners.com


     

          		 

    Lesen Sie auch

    Attachment


    Seite 4 von 4



    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors


    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    First patient dosed in monalizumab Phase 3 clinical trial triggers $50M payment from AstraZeneca - Seite 4 Milestone payment further bolsters Innate’s cash position  INTERLINK-1 represents first Phase 3 study examining IO approach in R/M SCCHN patients who have been treated with a platinum-based therapy and PD-(L)1 inhibitor Innate Pharma SA (Euronext …

    Auch bei Lesern beliebt

    Schreibe Deinen Kommentar

    Disclaimer